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ABSTRACT
Objective: The purpose of this study was to determine the effects of prophylactic near-infrared light therapy
from light-emitting diodes (LEDs) in pediatric bone marrow transplant (BMT) recipients. Background Data:
Oral mucositis (OM) is a frequent side effect of chemotherapy that leads to increased morbidity. Near-
infrared light has been shown to produce biostimulatory effects in tissues, and previous results using near-
infrared lasers have shown improvement in OM indices. However, LEDs may hold greater potential for
clinical applications. Materials and Methods: We recruited 32 consecutive pediatric patients undergoing mye-
loablative therapy in preparation for BMT. Patients were examined by two of three pediatric dentists trained
in assessing the Schubert oral mucositis index (OMI) for left and right buccal and lateral tongue mucosal sur-
faces, while the patients were asked to rate their current left and right mouth pain, left and right xerostomia,
and throat pain. LED therapy consisted of daily treatment at a fluence of 4 J/cm2 using a 670-nm LED array
held to the left extraoral epithelium starting on the day of transplant, with a concurrent sham treatment on
the right. Patients were assessed before BMT and every 2–3 days through posttransplant day 14. Outcomes
included the percentage of patients with ulcerative oral mucositis (UOM) compared to historical epidemiolog-
ical controls, the comparison of left and right buccal pain to throat pain, and the comparison between sides of
the buccal and lateral tongue OMI and buccal pain. Results: The incidence of UOM was 53%, compared to an
expected rate of 70–90%. There was also a 48% and 39% reduction of treated left and right buccal pain, re-
spectively, compared to untreated throat pain at about posttransplant day 7 (p < 0.05). There were no signifi-
cant differences between sides in OMI or pain. Conclusion: Although more studies are needed, LED therapy
appears useful in the prevention of OM in pediatric BMT patients.
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INTRODUCTION
ORAL MUCOSITIS (OM) is a frequent side effect ofchemotherapy in preparation for bone marrow transplant
(BMT). Ulcerations in the vulnerable oral mucosa produce se-
vere pain, oral superinfections that may lead to systemic infec-
tions, and compromise oral hydration and nutrition.1–3
Investigations into low-energy stimulation of tissues by
lasers have shown increased cellular activity during wound
healing, including increased collagen production4,5 and angio-
genesis.6 The data suggest that monochromatic, near-infrared
laser biostimulation produces its primary effect during the cell
proliferation phase,7,8 increasing mitochondria respiration
through stimulation of cytochrome oxidase.4,5,9 Production in-
creases have been seen in fibroblasts, collagen and procolla-
gen, growth factors, lymphocytes, and extracellular matrix—as
well as macrophage stimulation—with laser treatment.10–13
Optimal wavelengths for wound healing, as proven in previous
laser studies, include 680, 730, and 880 nm.4,5,11,14 Addition-
ally, previous studies have shown that use of helium-neon
lasers in BMT recipients significantly decreases the severity
and duration of ulcerative mucositis.15–17
Recently, light-emitting diodes (LEDs) have been shown to
be a safe, efficient, lightweight, and less-expensive alternative
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to treat wounds.18 Originally developed for NASA plant
growth experiments in space, LEDs can be designed to emit
monochromatic light at wavelengths shown to be effective in
laser light to treat wounds.19 LEDs have several advantages
over lasers for clinical use. LEDs can be designed to emit a
combination of wavelengths optimal for wound healing. They
are compact, light, and require significantly less energy. Unlike
lasers, they can be arranged in large, flat arrays allowing for
the treatment of a wide, three-dimensional surface. The emit-
ted near-infrared light has been shown to penetrate up to 23 cm
of skin and muscle.4,5,20 Because LED light is produced out-of-
phase, it emits very little heat. Therefore, at intensities required
to penetrate deeper tissues, there is little risk of heat damage to
the treated epithelial tissues. Because of this nonsignificant
risk (NSR) of heat damage to tissues, including the retina, the
FDA has given NSR approval for therapeutic trials of LEDs in
humans.
There is mounting evidence that LED arrays at the same bio-
stimulatory wavelengths of previous laser studies have similar
biochemical effects. Wong-Riley et al. have demonstrated LED
stimulation of cytochrome c oxidase activity in tetrodotoxin-
poisoned neurons.21 Earlier reports from our group have shown
increased in vitro production of mouse-derived fibroblasts, rat-
derived osteoblasts, rat-derived skeletal muscle cells, and nor-
mal human epithelial cells with LED treatment.18,22–24
In our latest in vivo studies18 using an ischemic wound
model in rats, we demonstrated decreased healing time of stan-
dardized wounds. Preliminary experiments on human wounds
produced significant decreases in healing time in crewmem-
bers aboard a U.S. Navy submarine and improvement in mus-
culoskeletal training injuries in Navy SEAL team members
with LED treatment. Lastly, preliminary data on pediatric
BMT patients showed a 47% reduction in buccal pain of LED-
treated OM compared to the untreated throat.
Our purpose for this study is to determine objectively the
severity and extent of mucositis in LED-treated buccal and lat-
eral tongue mucosal surfaces compared to historical epidemio-
logical data. We also set out to compare perceived mouth pain
between the treated mouth and untreated throat as well as
mouth xerostomia.
MATERIALS AND METHODS
We studied the effect of prophylactic LED treatments in pe-
diatric patients undergoing chemotherapy in anticipation for
BMT. Subjects were recruited consecutively among the pa-
tients being treated by the Bone Marrow Transplant Program at
the Children’s Hospital of Wisconsin in Milwaukee, Wisconsin
from June 2000 to December 2001. The institutional review
boards of Children’s Hospital of Wisconsin and the Medical
College of Wisconsin accepted and approved the study design.
Eligible participants were pediatric patients undergoing
chemotherapy and/or radiation programs considered to be mye-
loablative in preparation for either autologous or allogenic
BMT; patients with the emotional, cognitive, and mental matu-
rity sufficient to tolerate light application and oral examination
without combativeness; and patients whose parents or guardians
were willing to give informed consent. Patients were excluded if
they did not wish to submit to the trial protocol, were pregnant,
had photophobia or were on medication that may cause epider-
mal or ocular photosensitivity, were younger than 2 years old, or
had significant pulmonary dysfunction such that there was a risk
of intubation during the first 21 days posttransplant.
Study population
Thirty-two patients were enrolled in the study (one patient
received a second BMT 4 months later). The study population
is summarized in Table 1. Mean age was 12.5 years, with a
range of 3–23 years. Sixty percent of patients had a diagnosis
of acute leukemia; other diagnoses included lymphoma, sar-
coma of various types, chronic leukemia, severe aplastic ane-
mia, myelodysplastic syndrome, neuroblastoma, and sickle
cell anemia.
The myeloablative preconditioning for the patients in our
sample is summarized in Table 2. Twenty-two patients (66%)
received total-body irradiation (TBI) in addition to chemother-
apy. A majority of patients (53%) received the combination
cytarabine-cyclophosphamide-TBI.
Characterization of the preconditioning regimen is impor-
tant in order to compare our results to historical controls. In the
longitudinal study of OM by Woo et al., high rates of ulcerative
oral mucositis (UOM) were seen in BMT patients undergoing
cytarabine-cyclophosphamide-TBI (67%); cyclophosphamide-
TBI (79%); and melphalan (100%).25 Similarly, Wingard, et al.
found a high rate of UOM (73%) in BMT patients undergoing
busulfan-cyclophosphamide regimens.26 Finally, in Barasch et
al., all 22 BMT patients had bilateral UOM despite single-
sided helium-neon laser treatments.27 All but one patient had
busulfan as part of their preparative regimen. From these data,
it is within reason to expect a 70–90% rate of UOM in our pa-
tient population.
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TABLE 1. PATIENT POPULATION
No. of
Characteristic patients
Male 20 (63%)
Female 12 (38%)
Age range (years) 2–23
Mean age (years) 12.5
Diagnosis
Leukemia
Acute lymphocytic leukemia 12 (38%)
Acute myleogenous leukemia 7 (22%)
Chronic lymphocytic leukemia 2 (6%)
Lymphoma
Hodgkin’s lymphoma 1 (3%)
Non-Hodgkin’s lymphoma 2 (6%)
Sarcoma 3 (9%)
Severe aplastic anemia 2 (6%)
Myelodysplastic syndrome 1 (3%)
Sickle cell anemia 1 (3%)
Neuroblastoma 1 (3%)
Total 32 (100%)
Trial design
Each patient enrolled in the study received a pre-BMT ex-
amination of their buccal and lateral tongue mucosa by two of
three pediatric dentists trained in assessing the Schubert Oral
Mucositis Index (OMI).28 Photographs of each side of the
mouth were taken, and each observer independently rated the
seven different categories for each side of the buccal and lat-
eral tongue mucosal surfaces. Observers scored, on a 0–3
scale, categories that included atrophy, edema/cellulitis, ery-
thema, hyperkeratosis, lichenoid formation, ulceration, and
pseudomembrane formation. The ulceration category was
scored according to the size (1 = <1 mm2, 2 = 1–2 mm2, and
3 = >3 mm2). Patients were also given a self-reported pain and
xerostomia (labeled “dryness”) sheet containing the Wong-
Baker “smiley face” scale29 for each set of the two symptoms.
Participants were asked to rate their current level of oral pain
located in the left cheek, the right cheek, and the throat. They
were then asked to rate their current level of oral xerostomia in
the left cheek and the right cheek.
After the patients received their BMT, they were examined
again and were asked to rate their mouth and throat pain as
well as their mouth xerostomia as described above. Patients
were assessed every Monday, Wednesday, and Friday through
posttransplant day 14. We selected a stop date of 14 days in
order to minimize the potential influence of mucosal changes
due to graft-versus-host disease (GVHD) associated with allo-
genic BMT.
Patients then began LED exposure therapy on the first
posttransplant day. LED treatment consisted of once per day
exposure to light emitted from a 7.62 cm 2 12.7 cm array of
LEDs (Quantum Devices, Barneveld, WI) at a wavelength of
670 nm with a homogeneous and consistent power exposure
of 56 mW/cm2. The array was held in close proximity
(within 1 cm) to the left extraoral epithelium of the cheek for
a time calculated to achieve an energy level of 4 J/cm2
(71 sec). All treatment sessions were conducted by trained
clinicians familiar with the protocol for the placement of the
LED array. Although no retinal damage from LEDs has been
reported in the literature, we used protective eyewear, both
to shield the patient’s eyes and to blind patients during each
treatment session. At the same treatment session, while the
patient continued to wear the opaque protective goggles, the
right side was treated for the same amount of time; however,
an obstructing piece of foil was placed between the LED
array and the patient. Both the patients and the observers
were blinded as to which side was the actively treated side.
Additionally, direct and scattered LED light would not be
able to penetrate the tissues of the throat, therefore giving us
an untreated control.
The outcomes of this study were the (1) percentage of pa-
tients with ulcerative mucositis compared to historical epi-
demiological controls, (2) the comparison of left and right
buccal pain to throat pain, (3) the comparison of OMI between
left and right buccal and left and right lateral tongue mucosal
surfaces, and (4) interobserver consistency.
Statistical analysis
At each observation, the total of the seven OMI categories
for each of the four sites were averaged between the two ob-
servers. At each observation posttransplant, the averaged total
OMI score at each site was subtracted from the baseline total
OMI average for each site. The same was done for the subjec-
tive pain and xerostomia scales.
To determine if differences between left and right sides in
the objective and subjective scales existed, we used a single-
sample, two-tailed Student’s t test of the differences of left and
right buccal OMI, tongue OMI, buccal pain, and mouth xero-
stomia. To ascertain if significant differences existed between
left and right buccal pain and throat pain, we used a paired,
two-tailed Student’s t test. Interobserver variance was mea-
sured through a single-sample, two-tailed Student’s t test of the
differences of each observation at each site between each ob-
server pair.
The presence of UOM and its severity were determined by
the maximum averaged ulceration score at any site during the
study period. Maximum average ulceration scores in the range
of 3.0–2.5 were counted as “severe;” ranges of 2.4–1.5 were
counted as “moderate;” ranges of 1.4–0.5 were counted as
“mild.” The absence of UOM required having no note of ulcer-
ation among any observer at all sites through the 14-day time
period.
RESULTS
Table 3 shows the results of the average difference of buccal
and lateral tongue OMI, pain, and xerostomia scores from base-
line at each observation number. There was no significance
found between the left and right of buccal OMI, lateral tongue
OMI, buccal xerostomia scale, or buccal pain scale at all obser-
vations. The measured OMIs are graphically represented in Fig-
ure 1. The buccal OMI peaks at observation 4, corresponding to
approximately post-transplant day 9. Lateral tongue OMI peaks
at observation 5, or posttransplant day 11–12. Because the buc-
cal and tongue mucosal surfaces are so different, no comparison
between them was made.
For the perceived pain data, there was significance (p < 0.05)
between left buccal pain and throat pain as well as between
right buccal pain and throat pain at observation 3 (Fig. 2). This
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TABLE 2. BMT PRECONDITIONING REGIMENS
No. of
Regimen patients
Cytarabine-cyclophosphamide-TBI 17 (53%)
Etoposide-melphalan-TBI 3 (9%)
Melphalan 3 (9%)
Cytarabine-cyclophosphamide 2 (6%)
Busulfan-cyclophosphamide-TBI 2 (6%)
Busulfan-cyclophosphamide 1 (3%)
Busulfan-fludrabine 1 (3%)
Etoposide-carmustine-cytarabine 1 (3%)
Thiotepa-topotecan-carboplatin 1 (3%)
Cytarabine 1 (3%)
corresponds to a 48% and 39% difference in left and right buc-
cal pain, respectively, compared to throat pain.
The incidence and severity of UOM in our study can be
found in Figure 3. There was a 53% incidence of UOM; most
of those (59%, 31% of all patients) were categorized as having
mild UOM. Although the study period was shortened to
14 days in order to minimize the influence of GVHD, four pa-
tients were diagnosed with the disease within the study period.
One patient was categorized as having “severe” UOM, while
the other three did not show evidence of UOM.
Interobserver variance analysis revealed a small, though sig-
nificant (p < 0.05) bias toward higher OMI scores for one ob-
server within one observer pair throughout the study. Although
this pair made the majority of the observations throughout the
study, the average difference between measurements was only
0.08, and the pair agreed with each other 61% of the time.
Analysis between the other two pairs of observers showed they
were not significantly different.
DISCUSSION
This study represents the first clinical trial of NASA-
developed LEDs used to treat OM due to myeloablative
therapy in pediatric BMT patients. LED treatment produced
a significant 48% and 39% reduction in treated left and right
buccal pain, respectively, compared to the untreated throat.
This corresponds to approximately posttransplant day 7,
which is consistent with our preliminary data for this
study.18
There was also a reduction in the expected incidence of
UOM based on historical epidemiological data (53% versus
70–90%). This decrease in the incidence of UOM from ex-
pected was noteworthy despite the fact that our measurement
for “mild” UOM was very sensitive, requiring only one ob-
server at any time noting ulceration. This coincides with a low
incidence of “moderate” (9%) and “severe” (13%) UOM in our
treated study population.
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TABLE 3. CALCULATED AVERAGE OMI, PAIN, AND XEROSTOMIA SCORES FROM BASELINE
Observation number
1 2 3 4 5 6
Average posttransplant day 1.8 6 0.2 4.5 6 0.2 6.7 6 0.1 8.9 6 0.2 11.5 6 0.2 13.5 6 0.1 p value
Left buccal OMI 0.4 6 0.2 1.0 6 0.2 1.2 6 0.2 1.4 6 0.4 1.5 6 0.5 1.2 6 0.5
Right buccal OMI 0.4 6 0.1 0.9 6 0.2 1.2 6 0.2 1.4 6 0.4 1.3 6 0.5 1.1 6 0.5
Left lateral tongue OMI 0.1 6 0.1 0.4 6 0.2 0.5 6 0.2 0.5 6 0.2 0.6 6 0.3 0.5 6 0.3
Right lateral tongue OMI 0.1 6 0.1 0.4 6 0.2 0.6 6 0.2 0.5 6 0.2 0.7 6 0.3 0.5 6 0.3
Left buccal xerostomia scale 20.5 6 0.4 0.8 6 0.4 1.1 6 0.5 0.3 6 0.5 1.0 6 0.6 0.0 6 0.6
Right buccal xerostomia scale 20.3 6 0.4 1.0 6 0.5 1.2 6 0.4 0.6 6 0.5 1.0 6 0.6 0.2 6 0.6
Left buccal pain scale 0.6 6 0.2 0.7 6 0.4 1.6 6 0.5a 0.8 6 0.6 1.5 6 0.7 0.2 6 0.6 <0.05
Right buccal pain scale 0.7 6 0.3 0.8 6 0.4 1.9 6 0.5a 1.3 6 0.5 1.7 6 0.6 0.3 6 0.6 <0.05
Throat pain scale 0.6 6 0.3 1.3 6 0.6 3.1 6 0.6a 1.8 6 0.5 1.4 6 0.6 0.6 6 0.6
aLeft and right buccal pain scale significant versus throat pain scale at observation 3.
Data format: average 6 standard error of the mean.
FIG. 1. Average difference from baseline of the OMI of left/right buccal and left/right lateral tongue mucosal surfaces. Error
bars represent standard errors of the mean.
The lack of significance between left and right sides of the
buccal OMI, lateral tongue OMI, buccal pain, and buccal xe-
rostomia is also important to note. This is consistent with the
deep tissue penetration of near-infrared light, treating both the
left as well as the right (where sham treatments occurred) oral
mucosa.
Despite the encouraging findings from this study, the proto-
col design had some disadvantages. Comparison of the OMI of
the treated buccal and lateral tongue mucosal surfaces to his-
torical epidemiological controls is difficult. Most studies in the
literature reported the entire OMI score as a function of time,
not OMI scores of specific sites. Also, the comparison between
buccal pain and throat pain may not be as reliable as comparing
buccal pain of different sides. Swallowing occurs frequently
throughout the day whereas buccal irritation can be controlled
more easily, perhaps causing a greater awareness of throat
pain. Finally, although the incidence of UOM was reduced
from expected rates based on epidemiological data, a random-
ized and blinded control group within the study would have
provided clearer results.
In response to these limitations, we have designed a larger,
multicentered, randomized phase 2, double-blinded trial with
patients used as their own concurrent control through the use
of an intra-oral shield. This shield will block irradiation of di-
rect and indirect LED light from the opposite side. This will
allow for a direct comparison of measured OMI as well as per-
ceived pain and xerostomia of treated and untreated buccal sur-
faces. We look forward with great anticipation to the results of
this trial.
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FIG. 2. Change in pain scale from baseline of left and right buccal pain compared to throat pain. Error bars represent standard
errors of the mean.
FIG. 3. Incidence of ulcerative oral mucositis in patients treated with LED light.
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